Compare Merck & Co., Inc. (MRK) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Williams-Sonoma, Inc. — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Williams-Sonoma, Inc. trades at $223.2 (market cap $26.30B). The key difference: Merck & Co., Inc. is far larger — about 11.7× Williams-Sonoma, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | WSM | |
|---|---|---|
Market Cap | $307.25B | $26.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $240.06 |
52-Week Low | $77.60 | $168.64 |
Enterprise Value | $350.66B | $27.14B |
Dividend Yield | 2.73% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Williams-Sonoma (WSM) trades at $221.13, down 3.19% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has shown volatility. Recent earnings beats and consistent dividend payments highlight operational strength amid consumer discretionary sector challenges noted in recent financial media coverage.
The outlook is mixed with solid fundamentals and analyst consensus near current price, but risks include consumer spending sensitivity and competitive pressures. Upside potential exists if earnings momentum continues, yet macroeconomic headwinds and sector underperformance pose near-term challenges for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
